Clinical Gastroenterology and Hepatology - Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease

Clinical Gastroenterology and Hepatology feed:

Copy the feed link and paste it into your aggregator

Subscribe to this podcast with iTunes

FREEBOX: in this box you can write freely what you wish: add links, text, HTML code through a visual editor from the admin section! You can optionally disable this feature if you don't need it...

AGA Institute

An engaging mix of author interviews and expert commentary on the latest articles from Clinical Gastroenterology and Hepatology, hosted by the journals' online editor, John F. Kuemmerle, MD, AGAF.

29-07-2009 (9.28 MB)

Duration: 13:27 m - Filetype: mp3 - Bitrate: 96 KBPS - Frequency: 44100 HZ

Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease

A meta-analysis paper in the August issue of CGH set out to determine the rate of non-Hodgkin's lymphoma in adult Crohn's disease (CD) patients who have received anti-TNF therapy, and compare it with that of a population-based registry and a populationof CD patients treated with immunomodulators. Dr. Kuemmerle speaks with the senior author of the paper, Dr. Bruce Sands of Massachusetts General Hospital and Harvard Medical School, Boston, MA.

Download